Bill Wexler's Dog Pound Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound

REFR 1.560

0.0%

3:50 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: mchip who wrote (2117)	7/14/1999 7:32:00 AM
From: Mike M	Read Replies (1) of 10293

Putting the merits or not of VPHM aside, don't you see VPHM as a competitor to GUMM? and with actual FDA trials. What were you trying to point out Mike? A competitor to Zicam...possibly...If they get through trials in 2001... But it only cuts cold time in half (versus 87% for Zicam), requires a prescription and will cost a ton of money as a result of development costs....Then I hear Hank say that it only works for about 50% of the viruses and Zicam's approach purportedly works for all viruses that invade the ICAM Receptor... However, that was not my point...the Insana piece was not nearly as specific to the limitations addressed by Frank....the Morgan Stanley analyst was exuberant. My guess is that the analyst was possibly too exuberant for a drug that has an awful lot of trials left and may work no better than Hank suggests. It is problematic whether the drug will ever see the light of day. The part about the billion dollar potential revenue is puzzling...and my guess, doubtful...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next